HC Wainwright Has Negative View of Altimmune FY2026 Earnings

Altimmune, Inc. (NASDAQ:ALT – Free Report) – Equities research analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Altimmune in a research note issued to investors on Tuesday, November 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.62) per share for the year, down from their previous forecast of ($0.56). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Altimmune’s Q4 2026 earnings at ($0.17) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.73) EPS, FY2028 earnings at ($0.67) EPS, FY2029 earnings at ($0.35) EPS and FY2030 earnings at ($0.09) EPS.

ALT has been the subject of several other reports. Evercore restated an “outperform” rating on shares of Altimmune in a research report on Wednesday, September 23rd. Wall Street Zen lowered Altimmune from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 14th. Weiss Ratings cut Altimmune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, November 13th. B. Riley Financial reaffirmed a “buy” rating on shares of Altimmune in a report on Friday, November 13th. Finally, Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research report on Friday, November 13th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Altimmune has an average rating of “Moderate Buy” and a consensus price target of $14.33.

View Our Latest Stock Analysis on Altimmune

Altimmune Trading Down 6.0%

Shares of ALT stock opened at $1.32 on Thursday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 23.93 and a current ratio of 23.93. Altimmune has a 52-week low of $1.32 and a 52-week high of $6.44. The company has a market capitalization of $257.83 million, a PE ratio of -1.84 and a beta of 0.16. The business’s fifty day moving average is $2.39 and its 200 day moving average is $3.05.

Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

Institutional Trading of Altimmune

A number of hedge funds have recently made changes to their positions in ALT. American Century Companies Inc. bought a new position in shares of Altimmune during the 3rd quarter valued at about $97,000. Aquatic Capital Management LLC purchased a new position in shares of Altimmune during the 3rd quarter valued at about $49,000. Goldman Sachs Group Inc. raised its holdings in shares of Altimmune by 12.0% during the 3rd quarter. Goldman Sachs Group Inc. now owns 2,479,456 shares of the company’s stock valued at $7,091,000 after buying an additional 265,006 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Altimmune by 14.7% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,720,000 shares of the company’s stock worth $4,919,000 after buying an additional 220,000 shares during the last quarter. Finally, R Squared Ltd lifted its position in Altimmune by 99.6% in the 3rd quarter. R Squared Ltd now owns 26,475 shares of the company’s stock worth $76,000 after buying an additional 13,211 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Jerome Durso purchased 30,700 shares of the firm’s stock in a transaction dated Friday, November 13th. The shares were purchased at an average price of $1.62 per share, with a total value of $49,734.00. Following the acquisition, the chief executive officer directly owned 93,200 shares of the company’s stock, valued at approximately $150,984. This represents a 49.12% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have purchased 50,700 shares of company stock valued at $82,334. 1.60% of the stock is owned by insiders.

Key Stories Impacting Altimmune

Investors following ALT have been watching these stories:

  • Positive Sentiment: Barclays initiated or reiterated a Buy view on Altimmune, offering a favorable analyst signal; the report details, including any price target, were not provided. Altimmune Gets a Buy from Barclays
  • Neutral Sentiment: Management will participate in a fireside chat at the Evercore Healthcare Conference on Dec. 1. The announcement may provide an opportunity for updates, but no new company data or guidance was disclosed. Altimmune to Participate in the Evercore Healthcare Conference
  • Negative Sentiment: HC Wainwright lowered its EPS forecasts across much of 2026–2028, including its FY2027 estimate to a loss of $0.73 per share from $0.63 and FY2028 to a loss of $0.67 from $0.63. The analyst retained a Buy rating, and improved estimates for 2029–2030 partly offset the near-term downgrades. The lowered forecasts could reinforce concerns about continued losses. Altimmune analyst estimate coverage

About Altimmune

(Get Free Report)

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.

Recommended Stories

Earnings History and Estimates for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.